Bio Path reported 677K in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Baxter International USD 58M 14M Sep/2025
Bio Path 677K 547K Mar/2026
Cipla INR 131.3M 9M Mar/2026
Compugen USD 954K 116K Sep/2025
CSL USD 215M 111M Dec/2025
Grifols EUR 156.07M 31.46M Sep/2025
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025